Literature DB >> 28708015

Relationship between PPARα mRNA expression and mitochondrial respiratory function and ultrastructure of the skeletal muscle of patients with COPD.

Jian-Qing Zhang1, Xiang-Yu Long1, Yu Xie2, Zhi-Huan Zhao1, Li-Zhou Fang1, Ling Liu1, Wei-Ping Fu1, Jing-Kui Shu1, Jiang-Hai Wu1, Lu-Ming Dai1.   

Abstract

Peripheral muscle dysfunction is an important complication in patients with chronic obstructive pulmonary disease (COPD). The objective of this study was to explore the relationship between the levels of peroxisome proliferator-activated receptor α (PPARα) mRNA expression and the respiratory function and ultrastructure of mitochondria in the vastus lateralis of patients with COPD. Vastus lateralis biopsies were performed on 14 patients with COPD and 6 control subjects with normal lung function. PPARα mRNA levels in the muscle tissue were detected by real-time PCR. A Clark oxygen electrode was used to assess mitochondrial respiratory function. Mitochondrial number, fractional area in skeletal muscle cross-sections, and Z-line width were observed via transmission electron microscopy. The PPARα mRNA expression was significantly lower in COPD patients with low body mass index (BMIL) than in both COPD patients with normal body mass index (BMIN) and controls. Mitochondrial respiratory function (assessed by respiratory control ratio) was impaired in COPD patients, particularly in BMIL. Compared with that in the control group, mitochondrial number and fractional area were lower in the BMIL group, but were maintained in the BMIN group. Further, the Z-line became narrow in the BMIL group. PPARα mRNA expression was positively related to mitochondrial respiratory function and volume density. In COPD patients with BMIN, mitochondria volume density was maintained, while respiratory function decreased, whereas both volume density and respiratory function decreased in COPD patients with BMIL. PPARα mRNA expression levels are associated with decreased mitochondrial respiratory function and volume density, which may contribute to muscle dysfunction in COPD patients.

Entities:  

Keywords:  PPARα; mitochondrial respiratory function; muscle ultrastructure; skeletal muscle atrophy

Mesh:

Substances:

Year:  2017        PMID: 28708015      PMCID: PMC5736346          DOI: 10.1080/21655979.2017.1346757

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  30 in total

Review 1.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

Review 2.  Respiratory and Limb Muscle Dysfunction in COPD.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  COPD       Date:  2015-08       Impact factor: 2.409

3.  Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease.

Authors:  Elisabeth B Swallow; Diana Reyes; Nicholas S Hopkinson; William D-C Man; Raphaël Porcher; Edward J Cetti; Alastair J Moore; John Moxham; Michael I Polkey
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

4.  Morphometric analyses of human muscle fiber types.

Authors:  M Sjöström; K A Angquist; A C Bylund; J Fridén; L Gustavsson; T Scherstén
Journal:  Muscle Nerve       Date:  1982-09       Impact factor: 3.217

5.  Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD.

Authors:  A H Remels; P Schrauwen; R Broekhuizen; J Willems; S Kersten; H R Gosker; A M Schols
Journal:  Eur Respir J       Date:  2007-04-25       Impact factor: 16.671

Review 6.  Skeletal muscle mitochondrial dysfunction during chronic obstructive pulmonary disease: central actor and therapeutic target.

Authors:  Alain Meyer; Joffrey Zoll; Anne Laure Charles; Anne Charloux; Frédéric de Blay; Pierre Diemunsch; Jean Sibilia; François Piquard; Bernard Geny
Journal:  Exp Physiol       Date:  2013-02-01       Impact factor: 2.969

Review 7.  Metabolic derangements in COPD muscle dysfunction.

Authors:  Luis Puente-Maestu; Alberto Lázaro; Blanca Humanes
Journal:  J Appl Physiol (1985)       Date:  2013-01-03

8.  Peroxisome proliferator-activated receptors as novel targets in lung disease.

Authors:  Maria G Belvisi; David J Hele
Journal:  Chest       Date:  2008-07       Impact factor: 9.410

Review 9.  Peroxisome proliferator-activated receptors: a therapeutic target in COPD?

Authors:  A H Remels; H R Gosker; P Schrauwen; R C Langen; A M Schols
Journal:  Eur Respir J       Date:  2008-03       Impact factor: 16.671

10.  Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD.

Authors:  H R Gosker; M K C Hesselink; H Duimel; K A Ward; A M W J Schols
Journal:  Eur Respir J       Date:  2007-04-11       Impact factor: 16.671

View more
  3 in total

1.  Growth retardation-responsive analysis of mRNAs and long noncoding RNAs in the liver tissue of Leiqiong cattle.

Authors:  Lingxuan Kong; Guangbin Liu; Ming Deng; Zhiquan Lian; Yinru Han; Baoli Sun; Yongqing Guo; Dewu Liu; Yaokun Li
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

2.  Carnitine palmitoyltransferase 1 (CPT1) alleviates oxidative stress and apoptosis of hippocampal neuron in response to beta-Amyloid peptide fragment Aβ25-35.

Authors:  Yiyun Ding; Hongxia Zhang; Zhaojun Liu; Qiuping Li; Yujiao Guo; Ye Chen; Yue Chang; Hongyan Cui
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  NMR Spectroscopy Identifies Chemicals in Cigarette Smoke Condensate That Impair Skeletal Muscle Mitochondrial Function.

Authors:  Ram B Khattri; Trace Thome; Liam F Fitzgerald; Stephanie E Wohlgemuth; Russell T Hepple; Terence E Ryan
Journal:  Toxics       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.